NN3201
Based on 1 Customer Validation
NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM). NN3201 is composed of 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonal antibody NN2101 (HY-P991293). NN3201 rapidly internalizes and inhibits stem cell factor (SCF)-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research[1][2].
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.15%
-
Stockage:
-80°C, protect from light
Voir tous les produits spécifiques à Isoform Caspase
More
Activité biologique
Description
In Vitro
NN3201 (1 µg/mL, 1 h) exhibits dose-dependent binding to c-Kit-high and c-Kit-medium cell lines, which saturated at 315 pM, with no binding observed to c-Kit-low or negative cell lines[1].
NN3201 (1 µg/mL, 0.5-24 h) internalizes rapidly (within 30 minutes) and continuously in c-Kit-positive GIST-T1 cells, with the signal increasing for up to 24 hours, but its internalization was c-Kit-dependent[1].
NN3201 (3-7 days) demonstrates potent, c-Kit-dependent cytotoxicity mediated by its MMAE payload in a panel of positive cell lines, with GI50 values of 0.09 nM (GIST-T1), 0.69 nM (GIST-430), 0.12 nM (GIST-430/654), and 17.06 nM (NCI-H1048)[1].
NN3201 (0.01-1 µg/mL, 1 h) dose-dependently decreases the SCF-mediated phosphorylation on c-Kit (Y719, Y568/570), Erk1/2, and Akt (S473) in NCI-H1048 cells, while only partially suppressing phosphorylation (pY568/570 c-Kit and pErk1/2) in GIST-430/654 cells[1].
NN3201 (1 µg/mL, 1-3 days) induces c-Kit degradation and signaling inhibition through continuous internalization, which triggered apoptosis, demonstrated by the increase in cleaved caspase-3 and caspase-7[1].
NN3201 (5 µg/mL, 24-48 h) induces cell cycle arrest in the G2/M and sub-G1 phases, which is attributed to the microtubule-disrupting action of its released MMAE payload[1].
NN3201 (4 µg/mL, 7 days) triggers a potent bystander effect, mediated by free MMAE released from NN3201-treated GIST-430/654 cells, which killed neighboring MCF7-GFP⁺ cancer cells with negligible c-Kit expression[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF7-GFP+ cells
-
Concentration:4 μg/mL
-
Incubation Time:7 days
-
Result:Exhibited negligible cytotoxicity (GI50 >20 µg/mL) against the c-Kit-negative MCF7-GFP⁺ cell line, consistent with its target-dependent mechanism and in sharp contrast to the potent activity of its free payload, MMAE (GI50 = 4.96 nM).
-
Cell Line:GIST-430/654 and NCI-H1048 cells
-
Concentration:1 μg/mL
-
Incubation Time:24 and 48 h
-
Result:Induced substantial cell cycle arrest at the G2/M phase and increased the sub-G1 population in both cell lines.
-
Cell Line:GIST-430/654 and MCI-H1048 cells
-
Concentration:1 μg/mL
-
Incubation Time:1, 2, and 3 days
-
Result:Induced a time-dependent degradation of c-Kit in both cell lines.
Increased levels of cleaved caspase-3 and caspase-7.
Eventually inhibited the c-Kit downstream signaling pathway by sustained internalization and degradation of the NN3201-c-Kit complex over 3 days.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with GIST-T1 cells[1]
-
Dosage:0.5, 1.5 and 3.0 mg/kg
-
Administration:i.v., Q10D x 3
-
Result:Completely regressed tumor volume for up to 112 days at 1.5 and 3 mg/kg, with Imatinib (HY-15463) (100 mg/kg, p.o., Q1D x 30) only inhibited tumor progression during the treatment period.
Induced no body weight loss but rather an increase as tumor size enlarges.
-
Animal Model:NOG mice (5-6 weeks old) subcutaneously injected with GIST-430/654 cells[1]
-
Dosage:1, 3 and 5 mg/kg
-
Administration:i.v., Q1W x 3
-
Result:Induced significant tumor shrinkage at 3 mg/kg and 5 mg/kg, and stably controlled until day 42 and 49, respectively.
Induced tumor growth inhibition (TGI) of 47.2% on day 21 at 1 mg/kg, which was similar to that by 30 mg/kg of Sunitinib (HY-10255A) (30 mg/kg, p.o., Q1D x 21; TGI of 45.2% on day 21).
Induced no body weight loss but rather an increase as tumor size enlarges.
-
Animal Model:Female NOD/SCID mice subcutaneously implanted with GS5108 tumors[1]
-
Dosage:3, 5 and 10 mg/kg
-
Administration:i.v., Q1W x 3
-
Result:Induced durable tumor stasis at 10 mg/kg, which was followed by significant tumor regression for up to 60 days.
Demonstrated superior in vivo efficacy over all standard-of-care (SoC) treatments in the 3rd line GIST models.
Induced no body weight loss but rather an increase as tumor size enlarges.
-
Animal Model:Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with NCI-H526 cells[1]
-
Dosage:1, 1.5, 2, 2.5 and 3 mg/kg
-
Administration:i.v., Q1W x 3
-
Result:Induced complete regression of the tumor with no regrowth after 70 and 84 days at 2.5 and 3 mg/kg.
Exhibited 84.9% of TGI compared to the vehicle control on day 17 at 2 mg/kg.
Induced no body weight loss but rather an increase as tumor size enlarges.
-
Animal Model:Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with NCI-H1048 cells[1]
-
Dosage:1, 3, and 5 mg/kg
-
Administration:i.v., Q1W x 3
-
Result:Showed TGI of 95.1 % on day 21 at 1 mg/kg, better than the combination of Carboplatin (HY-17393) (60 mg/kg, i.p., day 0 and 10) and Etoposide (HY-13629) (3 mg/kg. i.p., day 0~4 and 10~14; TGI = 70.51% on day 21).
Induced complete tumor remission for up to 35 days and 56 days at 3 mg/kg and 5 mg/kg, respectively.
Induced no body weight loss but rather an increase as tumor size enlarges.
-
Animal Model:Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with NCI-H1048 cells[1]
-
Dosage:5 mg/kg
-
Administration:i.v., Q1W x 3
-
Result:Was able to reduce the tumor volume to below baseline, whereas neither Topotecan (HY-13768) (0.83 mg/kg, i.p., BIW x 3) nor Irinotecan (HY-16562) (33 mg/kg, i.v., Q1W x 3) could achieve this.
Induced no body weight loss but rather an increase as tumor size enlarges.
-
Animal Model:Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with SHP-77 cells[1]
-
Dosage:1, 3, and 5 mg/kg
-
Administration:i.v., Q1W x 3
-
Result:Exhibited no in vivo potency in SHP-77 xenografts, where c-Kit expression is negligible, confirming its c-Kit driven property.
Induced no body weight loss but rather an increase as tumor size enlarges.
-
Animal Model:Female Hsd: Athymic Nude-Foxn1nu mice subcutaneously implanted with CTG-1252 tumors[1]
-
Dosage:1, 3, and 5 mg/kg
-
Administration:i.v., Q1W x 3
-
Result:Dose-dependently inhibited tumor growth.
Achieved 70 days of complete regression at 5 mg/kg.
Induced no body weight loss but rather an increase as tumor size enlarges.
-
Animal Model:Female Hsd: Athymic Nude-Foxn1nu mice subcutaneously implanted with CTG-2093 tumors[1]
-
Dosage:1, 3, and 5 mg/kg
-
Administration:i.v., Q1W x 3
-
Result:Induced tumor stasis until day 27 with TGI of 84.8% at 5 mg/kg.
Induced no body weight loss but rather an increase as tumor size enlarges.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
Appearance Liquid
-
SMILES
[NN3201]
-
Livraison
Shipping with dry ice.
-
Stockage
-80°C, protect from light
Protocole
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
-
Fiche technique (283 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)